C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple My

Core Viewpoint - The company presented Phase I clinical data for cemsidomide in multiple myeloma at the IMS Annual Meeting, indicating progress in clinical development [2][3]. Group 1: Presentation Overview - The conference call was led by Courtney Solberg, Associate Director of Investor Relations, with participation from key executives including Andrew Hirsch, President and CEO, and Len Reyno, Chief Medical Officer [2][3]. - The agenda included opening remarks, a detailed discussion of clinical data for cemsidomide, next steps in clinical development, and a Q&A session with additional participants [3]. Group 2: Clinical Data - Dr. Binod Dhakal, a clinical investigator for multiple myeloma, presented the Phase I clinical results during the IMS meeting [3].